<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02976051</url>
  </required_header>
  <id_info>
    <org_study_id>DAHANCA 33</org_study_id>
    <nct_id>NCT02976051</nct_id>
  </id_info>
  <brief_title>DAHANCA 33: Image Guided Dose-escalated Radiotherapy to Patients With Hypoxic HNSCC</brief_title>
  <official_title>DAHANCA 33: Functional Image Guided Dose-escalated Radiotherapy to Patients With Hypoxic Squamous Cell Carcinoma of the Head and Neck</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Danish Head and Neck Cancer Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Danish Head and Neck Cancer Group</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Aim: To improve curability of radiotherapy in HNSCC patients identified by hypoxic FAZA-PET
      scanning
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Prospective phase II study aiming to improve the outcome in hypoxic resistent patients
      identified by FAZA-PET.

      Inclusion:

      Patients must fulfill the following:

      Positive hypoxic FAZA-PET Scanning (as described in DAHANCA 24 - see citation) Stage III-IV,
      Squamous cell carcinoma of the larynx, pharynx or oral cavity (HPVneg (oropharynx) Indication
      for hyperfractionated accelerated radiotherapy with concommitant cis-platin and nimorazole
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 2017</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Loco-regional failure</measure>
    <time_frame>Year 3</time_frame>
    <description>loco-regional failure defined as persistent or recurrent disease in tumor and/or regional lymphnode sites (within the radiotherapy treated volume). The primary endpoint did not include the effect of a successful procedure with salvage surgery (no primary neck dissection was allowed).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>Year 3</time_frame>
    <description>Death from all causes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute radiation related morbidity</measure>
    <time_frame>Month 3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Late radiation related morbidity</measure>
    <time_frame>Year 3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease-specific death</measure>
    <time_frame>Year 3</time_frame>
    <description>Disease-specific death is defined as death from or with the cancer in question;</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Locally Advanced Head and Neck Cancer</condition>
  <condition>Radiotherapy</condition>
  <arm_group>
    <arm_group_label>Treatment with HART-CN</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HART-CN: Hyperfractionated accelerated radiotherapy with weekly concommitant cisplatin and nimorazole</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>HART-CN</intervention_name>
    <description>HART-CN: Hyperfractionated accelerated radiotherapy with weekly concommitant cis-platin and daily nimorazole</description>
    <arm_group_label>Treatment with HART-CN</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Stage III-IV larynx, pharynx, oral cavity

          -  Hypoxic FAZA-PET positive

          -  Indication for primary radio-chemotherapy

          -  Informed consent

        Exclusion Criteria:

          -  HPV positive oropharynx cancer

          -  Primary surgery
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jens Overgaard, MD, DMSc</last_name>
    <phone>+45 78462629</phone>
    <email>jens@oncology.au.dk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mette Saksoe, MD</last_name>
    <phone>+45 78462629</phone>
    <email>mette.saksoe@oncology.au.dk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Experimental Clinical Oncology, Aarhus University Hospital</name>
      <address>
        <city>Aarhus</city>
        <zip>8000 C</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jens Overgaard, Prof., MD</last_name>
      <phone>+45 7846 2629</phone>
      <email>jens@oncology.au.dk</email>
    </contact>
    <contact_backup>
      <last_name>Mette Saxø, MD</last_name>
      <phone>+89492619</phone>
      <email>mette.saksoe@oncology.au.dk</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <results_reference>
    <citation>Mortensen LS, Johansen J, Kallehauge J, Primdahl H, Busk M, Lassen P, Alsner J, Sørensen BS, Toustrup K, Jakobsen S, Petersen J, Petersen H, Theil J, Nordsmark M, Overgaard J. FAZA PET/CT hypoxia imaging in patients with squamous cell carcinoma of the head and neck treated with radiotherapy: results from the DAHANCA 24 trial. Radiother Oncol. 2012 Oct;105(1):14-20. doi: 10.1016/j.radonc.2012.09.015. Epub 2012 Oct 16.</citation>
    <PMID>23083497</PMID>
  </results_reference>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 22, 2016</study_first_submitted>
  <study_first_submitted_qc>November 28, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 29, 2016</study_first_posted>
  <last_update_submitted>July 26, 2017</last_update_submitted>
  <last_update_submitted_qc>July 26, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 28, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Danish Head and Neck Cancer Group</investigator_affiliation>
    <investigator_full_name>Jens Overgaard</investigator_full_name>
    <investigator_title>Professor, MD DMSc</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Head and Neck Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

